| 13.55 -0.03 (-0.22%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.05 | 1-year : | 19.91 |
| Resists | First : | 14.6 | Second : | 17.05 |
| Pivot price | 11.81 |
|||
| Supports | First : | 12.12 | Second : | 10.59 |
| MAs | MA(5) : | 12.3 |
MA(20) : | 12.15  |
| MA(100) : | 10.2 |
MA(250) : | 7.73 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 65.9 |
D(3) : | 42.7 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 15.39 | Low : | 3.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CMPS ] has closed Bollinger Bands are 0.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.78 - 13.86 | 13.86 - 13.94 |
| Low: | 13.08 - 13.17 | 13.17 - 13.24 |
| Close: | 13.43 - 13.56 | 13.56 - 13.69 |
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Thu, 06 Aug 2026
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Thu, 06 Aug 2026
COMPASS Pathways plc (CMPS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 06 Aug 2026
RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating - marketscreener.com
Thu, 06 Aug 2026
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026 - Business Wire
Thu, 06 Aug 2026
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - Business Wire
Wed, 05 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 135 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 72.7 (%) |
| Shares Short | 12,840 (K) |
| Shares Short P.Month | 8,360 (K) |
| EPS | -3.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.7 % |
| Return on Equity (ttm) | -68.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -160 (M) |
| Levered Free Cash Flow | 33 (M) |
| PE Ratio | -4.32 |
| PEG Ratio | 0 |
| Price to Book value | 5.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|